DLQIad: A New Quality-of-Life Questionnaire for Patients with Atopic Dermatitis
Journal of Clinical Medicine · 07.11.2026 · 15 (21) · 8695
DOI: 10.3390/jcm15218695 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.11.2026. Verfasst von Ersilia Tolino und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Dermatology 'Daniele Innocenzi', Fiorini Hospital, 04019 Terracina, Italy. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin disease that substantially impairs health-related quality of life (HRQoL). The Dermatology Life Quality Index (DLQI) is widely used, but it is a generic dermatology instrument and may not capture the full patient-reported burden of AD. This study developed an exploratory AD-specific questionnaire (DLQIad), evaluated its internal consistency, and compared its responsiveness with that of the DLQI in patients receiving dupilumab.
Methods
In this real-life, single-centre observational study, 102 adults with moderate-to-severe AD completed the DLQIad and DLQI and underwent Eczema Area and Severity Index (EASI) assessment before and after 16 weeks of dupilumab treatment. Pre–post differences were evaluated using Wilcoxon signed-rank tests. Internal consistency was assessed using Cronbach’s alpha. Responsiveness was quantified using the standardised response mean (SRM) and the standardised mean-change effect size, and paired patient-level bootstrap resampling was used to compare the DLQIad and DLQI.
Results
Mean EASI decreased from 27.84 to 5.96, mean DLQI from 15.76 to 2.35, and mean DLQIad from 44.24 to 8.19 (all p < 0.001). Cronbach’s alpha was 0.945 at baseline and 0.929 at week 16. The DLQIad showed an SRM of 2.31 compared with 1.89 for the DLQI; the paired difference was 0.421 (BCa 95% CI, 0.134–0.750; p = 0.009). The corresponding difference in standardised mean-change effect size was 0.362 (BCa 95% CI, −0.014–0.762; p = 0.065). Changes in EASI were significantly associated with changes in both patient-reported instruments, without a significant difference between their standardised regression coefficients.
Conclusions
The DLQIad demonstrated high internal consistency and preliminary evidence of responsiveness in this selected cohort. Its apparent advantage over the DLQI was dependent on the responsiveness metric used. Structural validity, test–retest reliability, interpretability, and score thresholds require evaluation in independent multicentre samples before clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Dermatology 'Daniele Innocenzi', Fiorini Hospital, 04019 Terracina, Italy.
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Polo Pontino, 04100 Latina, Italy.
- Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Dermatological Research Hospital, 00167 Rome, Italy.
ORCID-Profile: Antonio Di Guardo, Umberto Gallo, Ilaria Proietti, Nevena Skroza
Zitieren
APA
Tolino, E., Di Guardo, A., Gallo, U., Bernardini, N., Proietti, I., & Skroza, N. (2026). DLQIad: A New Quality-of-Life Questionnaire for Patients with Atopic Dermatitis. Journal of Clinical Medicine, 15(21), 8695. https://doi.org/10.3390/jcm15218695
Vancouver
Tolino E, Di Guardo A, Gallo U, Bernardini N, Proietti I, Skroza N. DLQIad: A New Quality-of-Life Questionnaire for Patients with Atopic Dermatitis. Journal of Clinical Medicine. 2026;15(21):8695. doi:10.3390/jcm15218695
BibTeX
@article{Tolino2026,
author = {Tolino, Ersilia and Di Guardo, Antonio and Gallo, Umberto and Bernardini, Nicoletta and Proietti, Ilaria and Skroza, Nevena},
title = {DLQIad: A New Quality-of-Life Questionnaire for Patients with Atopic Dermatitis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8695},
doi = {10.3390/jcm15218695}
}
EUVIMED